DE60132343D1 - Fgf-2 zur behandlung von erkrankungen der peripheralen arterien - Google Patents

Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Info

Publication number
DE60132343D1
DE60132343D1 DE60132343T DE60132343T DE60132343D1 DE 60132343 D1 DE60132343 D1 DE 60132343D1 DE 60132343 T DE60132343 T DE 60132343T DE 60132343 T DE60132343 T DE 60132343T DE 60132343 D1 DE60132343 D1 DE 60132343D1
Authority
DE
Germany
Prior art keywords
fgf
artery disease
peripheral artery
compositions
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60132343T
Other languages
English (en)
Other versions
DE60132343T2 (de
Inventor
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60132343D1 publication Critical patent/DE60132343D1/de
Publication of DE60132343T2 publication Critical patent/DE60132343T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60132343T 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien Expired - Fee Related DE60132343T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US213504P 2000-06-22
US26457201P 2001-01-26 2001-01-26
US264572P 2001-01-26
US27654901P 2001-03-16 2001-03-16
US276549P 2001-03-16
US886856 2001-06-21
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease
PCT/US2001/019978 WO2001098346A2 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Publications (2)

Publication Number Publication Date
DE60132343D1 true DE60132343D1 (de) 2008-02-21
DE60132343T2 DE60132343T2 (de) 2008-12-24

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132343T Expired - Fee Related DE60132343T2 (de) 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Country Status (8)

Country Link
US (3) US20020115603A1 (de)
EP (1) EP1324766B1 (de)
JP (1) JP2004501164A (de)
AT (1) ATE383168T1 (de)
AU (1) AU2001268680A1 (de)
CA (1) CA2414020A1 (de)
DE (1) DE60132343T2 (de)
WO (1) WO2001098346A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
US7432243B2 (en) 2002-04-08 2008-10-07 The Scripps Research Institute Truncated 24kDa basic fibroblast growth factor
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
US20070037872A1 (en) * 2005-06-29 2007-02-15 Mars, Incorporated Inducing peripheral blood vesel vasodilation
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
US9310985B2 (en) 2008-05-15 2016-04-12 Boston Scientific Neuromodulation Corporation System and method for determining target stimulation volumes
ES2523740T3 (es) 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
US8461111B2 (en) * 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2470258B1 (de) 2009-08-27 2017-03-15 The Cleveland Clinic Foundation System und verfahren zur beurteilung einer gewebeaktivierungsregion
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
WO2011159688A2 (en) 2010-06-14 2011-12-22 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
US9227074B2 (en) 2012-08-28 2016-01-05 Boston Scientific Neuromodulation Corporation Parameter visualization, selection, and annotation interface
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
AU2012294364A1 (en) 2011-08-09 2014-03-20 Boston Scientific Neuromodulation Corporation Remote control for blind clinical trials of electrical stimulation
EP2879757B1 (de) 2012-08-04 2019-06-26 Boston Scientific Neuromodulation Corporation Systeme und verfahren zum speichern und übertragen von registrierungen sowie atlas- und anleitungsinformationen zwischen medizinischen vorrichtungen
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US10213214B2 (en) 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US10342551B2 (en) 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US9949738B2 (en) * 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
WO2016191436A1 (en) 2015-05-26 2016-12-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
WO2017003947A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US20160375248A1 (en) 2015-06-29 2016-12-29 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
EP3359252B1 (de) 2015-10-09 2020-09-09 Boston Scientific Neuromodulation Corporation System und verfahren zur kartierung klinischer wirkungen für direktionale stimulationselektroden
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
EP3458152B1 (de) 2016-06-24 2021-04-21 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur visuellen analyse klinischer wirkungen
WO2018044881A1 (en) 2016-09-02 2018-03-08 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
AU2017341910B2 (en) 2016-10-14 2020-05-14 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
CN110167629B (zh) 2017-01-03 2023-07-18 波士顿科学神经调制公司 用于选择兼容mri的刺激参数的系统和方法
ES2821752T3 (es) 2017-01-10 2021-04-27 Boston Scient Neuromodulation Corp Sistemas y procedimientos para crear programas de estimulación en base a áreas o volúmenes definidos por el usuario
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
WO2018187090A1 (en) 2017-04-03 2018-10-11 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
US20200384079A1 (en) * 2017-04-26 2020-12-10 University Of Cincinnati Compositions of Fibroblast Growth Factor LIgands and Methods of Treating Patients Undergoing Ischemia-Reperfusion Therapy
CN110944710B (zh) 2017-07-14 2023-12-29 波士顿科学神经调制公司 估计电刺激的临床效果的系统和方法
US10960214B2 (en) 2017-08-15 2021-03-30 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
WO2019210202A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
ATE198979T1 (de) 1994-10-12 2001-02-15 Focal Inc Zielgerichte verabreichung mittels biologisch abbaubarer polymere
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
JP5329729B2 (ja) * 1998-09-03 2013-10-30 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Also Published As

Publication number Publication date
JP2004501164A (ja) 2004-01-15
EP1324766B1 (de) 2008-01-09
WO2001098346A2 (en) 2001-12-27
AU2001268680A1 (en) 2002-01-02
ATE383168T1 (de) 2008-01-15
DE60132343T2 (de) 2008-12-24
WO2001098346A3 (en) 2003-05-01
US20070135348A1 (en) 2007-06-14
CA2414020A1 (en) 2001-12-27
US20040209817A1 (en) 2004-10-21
US7186407B2 (en) 2007-03-06
EP1324766A2 (de) 2003-07-09
US20020115603A1 (en) 2002-08-22
US7541337B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
DK0710114T3 (da) Koagulationsfaktor VIII-formulering
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
DE60327771D1 (de) Glp-1 und behandlungsmethode für diabetes
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
WO2002022163A1 (fr) Remedes contre des maladies ischemiques
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
EP1894570A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie
RU2130773C1 (ru) Способ лечения саркомы капоши
RU2140270C1 (ru) Способ лечения идиопатического типа саркомы капоши
RU2020123217A (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
RU2021130022A (ru) Применение эпидермального фактора роста при лечении диабетической язвы стопы
RU2006142622A (ru) Способ лечения острого инфаркта миокарда
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee